Spyre Therapeutics, Inc. announced a poster presentation at the 20th Congress of the European Crohn's and Colitis Organisation (ECCO), held February 19-22, 2025. The presentation highlighted preclinical findings supporting the combination potential for its SPY120 program, which combines anti-α4β7 and anti-TL1A antibodies.
The data showed that combined inhibition of α4β7 integrin and TL1A cytokine was superior to either monotherapy in mouse models of colitis, demonstrating additive or greater than additive efficacy. This supports the company's strategy to develop combination therapies for inflammatory bowel disease (IBD).
Coadministration of SPY001 and SPY002 in non-human primates showed no drug-drug pharmacokinetic effects, indicating the potential for quarterly or twice-annual dosing of SPY120 in humans. Spyre expects to test this combination in its Phase 2 trial in ulcerative colitis patients, anticipated to begin mid-year.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.